Home LiteratureArticle Details
PMID: 23723299 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

HMGB1 in cancer: good, bad, or both?

Clinical cancer research : an official journal of the American Association for Cancer Research ·Vol. 19 ·No. 15 ·2013-08-01 ·Pages 4046-57

Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D

Abstract

Forty years ago, high mobility group box 1 (HMGB1) was discovered in calf thymus and named according to its electrophoretic mobility in polyacrylamide gels. Now, we know that HMGB1 performs dual functions. Inside the cell, HMGB1 is a highly conserved chromosomal protein acting as a DNA chaperone. Outside of the cell, HMGB1 is a prototypical damage-associated molecular pattern, acting with cytokines, chemokines, and growth factors. During tumor development and in cancer therapy, HMGB1 has been reported to play paradoxical roles in promoting both cell survival and death by regulating multiple signaling pathways, including inflammation, immunity, genome stability, proliferation, metastasis, metabolism, apoptosis, and autophagy. Here, we review the current knowledge of both HMGB1's oncogenic and tumor-suppressive roles and the potential strategies that target HMGB1 for the prevention and treatment of cancer.

MeSH Terms
Apoptosis/genetics Autophagy/genetics Cell Nucleus/metabolism Cell Survival/genetics Chemokines/metabolism Cytokines/metabolism HMGB1 Protein/genetics,metabolism Humans Intercellular Signaling Peptides and Proteins/metabolism Neoplasms/genetics,pathology,therapy Signal Transduction/genetics
Chemicals
Chemokines Cytokines HMGB1 Protein HMGB1 protein, human Intercellular Signaling Peptides and Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Kang Rui
Department of Surgery, University of Pittsburgh Cancer Institute, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Zhang Qiuhong
Zeh Herbert J
Lotze Michael T
Tang Daolin
References (75)
75 references, click to expand
  1. Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B.
    Carcinogenesis. 2011 Aug;32(8):1167-75 PMID: 21642357
  2. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.
    Hepatology. 2012 Jun;55(6):1863-75 PMID: 22234969
  3. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis.
    Cancer Cell. 2006 Jul;10(1):51-64 PMID: 16843265
  4. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
    Nat Rev Immunol. 2005 Apr;5(4):331-42 PMID: 15803152
  5. Priming the nucleosome: a role for HMGB proteins?
    EMBO Rep. 2003 Feb;4(2):131-6 PMID: 12612600
  6. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system.
    Nat Med. 2012 Mar 06;18(3):344-6; author reply 346 PMID: 22395693
  7. Ethyl pyruvate administration inhibits hepatic tumor growth.
    J Leukoc Biol. 2009 Sep;86(3):599-607 PMID: 19584311
  8. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
    Nat Med. 2007 Sep;13(9):1050-9 PMID: 17704786
  9. HMGB1 gene knockout in mouse embryonic fibroblasts results in reduced telomerase activity and telomere dysfunction.
    Chromosoma. 2012 Aug;121(4):419-31 PMID: 22544226
  10. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1.
    Oncogene. 2013 Jan 17;32(3):363-74 PMID: 22391561
  11. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output.
    PLoS Biol. 2011 Jun;9(6):e1001086 PMID: 21738444
  12. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
    PLoS Med. 2009 Jan 13;6(1):e10 PMID: 19143470
  13. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.
    EMBO J. 2010 Jul 7;29(13):2242-52 PMID: 20526283
  14. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells.
    Leukemia. 2011 Jan;25(1):23-31 PMID: 20927132
  15. HMGB1 is a therapeutic target for sterile inflammation and infection.
    Annu Rev Immunol. 2011;29:139-62 PMID: 21219181
  16. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  17. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
    Science. 2011 Dec 16;334(6062):1573-7 PMID: 22174255
  18. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.
    Cancer Res. 2002 Aug 15;62(16):4805-11 PMID: 12183440
  19. High-mobility group box 1 is essential for mitochondrial quality control.
    Cell Metab. 2011 Jun 8;13(6):701-11 PMID: 21641551
  20. Rage signalling promotes intestinal tumourigenesis.
    Oncogene. 2013 Feb 28;32(9):1202-6 PMID: 22469986
  21. High-mobility group box 1, oxidative stress, and disease.
    Antioxid Redox Signal. 2011 Apr 1;14(7):1315-35 PMID: 20969478
  22. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.
    Oncogene. 2010 Sep 23;29(38):5299-310 PMID: 20622903
  23. Role of HMGB1 in apoptosis-mediated sepsis lethality.
    J Exp Med. 2006 Jul 10;203(7):1637-42 PMID: 16818669
  24. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein.
    Immunity. 2008 Jul 18;29(1):21-32 PMID: 18631454
  25. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Nature. 1999 Jun 17;399(6737):708-12 PMID: 10385126
  26. HMGB1 promotes drug resistance in osteosarcoma.
    Cancer Res. 2012 Jan 1;72(1):230-8 PMID: 22102692
  27. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
    Nature. 2000 May 18;405(6784):354-60 PMID: 10830965
  28. High-mobility group box 1 and cancer.
    Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40 PMID: 20123075
  29. Autophagy suppresses tumor progression by limiting chromosomal instability.
    Genes Dev. 2007 Jun 1;21(11):1367-81 PMID: 17510285
  30. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Cancer Res. 2012 Aug 15;72(16):3967-76 PMID: 22700877
  31. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer.
    Acta Pharmacol Sin. 2007 Dec;28(12):1957-67 PMID: 18031610
  32. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.
    Oncogene. 2014 Jan 30;33(5):567-77 PMID: 23318458
  33. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.
    Nucleic Acids Res. 2009 Apr;37(7):2070-86 PMID: 19223331
  34. HMGB1: the jack-of-all-trades protein is a master DNA repair mechanic.
    Mol Carcinog. 2009 Jul;48(7):571-80 PMID: 19360789
  35. p53/HMGB1 complexes regulate autophagy and apoptosis.
    Cancer Res. 2012 Apr 15;72(8):1996-2005 PMID: 22345153
  36. HMGB1-facilitated p53 DNA binding occurs via HMG-Box/p53 transactivation domain interaction, regulated by the acidic tail.
    Structure. 2012 Dec 5;20(12):2014-24 PMID: 23063560
  37. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release.
    J Exp Med. 2012 Aug 27;209(9):1519-28 PMID: 22869893
  38. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.
    Nat Immunol. 2007 May;8(5):487-96 PMID: 17417641
  39. Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy.
    Blood. 2013 Feb 28;121(9):1622-32 PMID: 23287860
  40. A dual role for UVRAG in maintaining chromosomal stability independent of autophagy.
    Dev Cell. 2012 May 15;22(5):1001-16 PMID: 22542840
  41. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.
    EMBO Rep. 2002 Oct;3(10):995-1001 PMID: 12231511
  42. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
    Cancer Res. 2011 Jul 15;71(14):4821-33 PMID: 21602432
  43. HMGB1: a two-headed signal regulating tumor progression and immunity.
    Curr Opin Immunol. 2008 Oct;20(5):518-23 PMID: 18599281
  44. RAGE signaling sustains inflammation and promotes tumor development.
    J Exp Med. 2008 Feb 18;205(2):275-85 PMID: 18208974
  45. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.
    Virchows Arch. 2005 Apr;446(4):411-5 PMID: 15789216
  46. High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.
    Mol Pharmacol. 2008 Jan;73(1):260-9 PMID: 17951356
  47. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.
    J Biol Chem. 1995 Oct 27;270(43):25752-61 PMID: 7592757
  48. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.
    Nat Immunol. 2012 Sep;13(9):832-42 PMID: 22842346
  49. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.
    Science. 2009 Mar 27;323(5922):1722-5 PMID: 19264983
  50. Endogenous HMGB1 regulates autophagy.
    J Cell Biol. 2010 Sep 6;190(5):881-92 PMID: 20819940
  51. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma.
    Virchows Arch. 2007 Mar;450(3):287-95 PMID: 17235565
  52. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.
    J Pathol. 2002 Feb;196(2):163-70 PMID: 11793367
  53. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin.
    EMBO J. 2007 Feb 21;26(4):1129-39 PMID: 17268551
  54. Yeast Nhp6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability.
    Curr Biol. 2005 Jan 11;15(1):68-72 PMID: 15649368
  55. HMGB1 and RAGE in inflammation and cancer.
    Annu Rev Immunol. 2010;28:367-88 PMID: 20192808
  56. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer.
    Pathobiology. 2009;76(4):155-62 PMID: 19571604
  57. Deconvoluting the context-dependent role for autophagy in cancer.
    Nat Rev Cancer. 2012 Apr 26;12(6):401-10 PMID: 22534666
  58. The extracellular release of HMGB1 during apoptotic cell death.
    Am J Physiol Cell Physiol. 2006 Dec;291(6):C1318-25 PMID: 16855214
  59. PAMPs and DAMPs: signal 0s that spur autophagy and immunity.
    Immunol Rev. 2012 Sep;249(1):158-75 PMID: 22889221
  60. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
    Nature. 2002 Jul 11;418(6894):191-5 PMID: 12110890
  61. Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.
    J Immunol. 2011 Jul 1;187(1):118-25 PMID: 21642542
  62. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy.
    Eur J Cancer. 2013 Feb;49(3):741-51 PMID: 23040637
  63. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus.
    J Biol Chem. 2007 Jun 15;282(24):17845-54 PMID: 17430886
  64. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia.
    Proc Natl Acad Sci U S A. 2012 May 1;109(18):7031-6 PMID: 22509024
  65. Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer.
    Cancer Res. 2013 Jan 15;73(2):629-39 PMID: 23108142
  66. A role for mitochondria in NLRP3 inflammasome activation.
    Nature. 2011 Jan 13;469(7329):221-5 PMID: 21124315
  67. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.
    J Exp Med. 2005 Apr 4;201(7):1135-43 PMID: 15795240
  68. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.
    Cell Death Differ. 2010 Apr;17(4):666-76 PMID: 19834494
  69. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1.
    J Leukoc Biol. 2007 Mar;81(3):741-7 PMID: 17135572
  70. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release.
    Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7 PMID: 20547845
  71. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4.
    J Exp Med. 2012 Mar 12;209(3):551-63 PMID: 22370717
  72. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β.
    EMBO J. 2011 Nov 08;30(23):4701-11 PMID: 22068051
  73. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.
    EMBO J. 2003 Oct 15;22(20):5551-60 PMID: 14532127
  74. PKR-dependent inflammatory signals.
    Sci Signal. 2012 Oct 23;5(247):pe47 PMID: 23092889
  75. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.
    Cancer Res. 2012 Jul 1;72(13):3290-301 PMID: 22552293
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1557-3265
DOI
10.1158/1078-0432.CCR-13-0495
Published
2013-08-01
Epub
2013-00-30
Pages
4046-57
Language
English
Region
United States
NLM ID
9502500
PMCID
PMC3732559
Subset
IM
Grants
NCI NIH HHS · R01 CA160417 · United States
NCATS NIH HHS · UL1 TR000005 · United States
NCI NIH HHS · R01CA160417 · United States
External Links
PubMed source DOI: 10.1158/1078-0432.CCR-13-0495 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2